- $118.57m
- $57.63m
- $194.06m
LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs
Brief: LifeMD Inc Q2 Revenue USD 47.3 Million Vs. IBES Estimate USD 49.2 Million
LifeMD Inc expected to post a loss of 15 cents a share - Earnings Preview
LifeMD Q1 revenue beats estimates on record telehealth subscriber additons
Brief: LifeMD Q1 Adjusted EBITDA USD -4.5 Million Vs. IBES Estimate USD -4.66 Million
LifeMD rises after adding new daily obesity pill to weight management program
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US (updated)
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
Brief: Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients
Brief: LifeMD Inc Announced Appointment Of Atul Kavthekar As Chief Financial Officer
LifeMD Q4 revenue rises but misses estimates
Brief: Lifemd Announces Closing Of $50 Million Revolving Credit Facility With Citizens Bank, N.A.
Telehealth stocks rise as Novo Nordisk launches Wegovy pill in US
Insight: Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s
U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler
LifeMD falls after cutting FY revenue forecast, Q3 revenue miss
Telehealth firm LifeMD's Q3 revenue misses estimates
Brief: LifeMd To Offer Market-Leading Pricing For Glp-1 Medications Wegovy And Ozempic In Continued Collaboration With Novo Nordisk
Brief: LifeMD Files Non-Timely 10-Q With US SEC